The content on this site is intended for healthcare professionals only
Dr Natalia Gandur speaks to ecancer about the updates in renal cancer from ASCO 2026.
She explains that this year the general theme focused on refining adjuvant treatment decisions through improved risk stratification, biomarker development, and broader evidence across renal cancer subtypes.
Dr Gandur covers adjuvant RCC and biomarkers, radical treatment approaches for oligometastatic disease, non-clear cell renal cancer, and patient-centred future directions.
Challenges in high-risk NMIBC: Addressing current unmet needs to optimise patient care
Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer
Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in RCC
AMVAC plus nivolumab in muscle-invasive bladder cancer preserves bladder and predicts metastatic control with ctDNA
225Ac-PSMA-trillium shows high PSA response and favourable safety in metastatic castration-resistant prostate cancer
Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high bladder preservation and survival in MIBC
Addition of radical prostatectomy to systemic treatment improves survival in oligometastatic prostate cancer
NeuroSAFE-guided RARP improves surgical precision for patients with localised prostate cancer
TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy
